Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs
- 5 January 2021
- journal article
- research article
- Published by Elsevier BV in Digestive and Liver Disease
- Vol. 53 (3), 277-282
- https://doi.org/10.1016/j.dld.2020.12.120
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Uneventful Course in Patients With Inflammatory Bowel Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak in Northern ItalyGastroenterology, 2020
- High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Requiring Invasive Mechanical VentilationObesity, 2020
- Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in ChengduJournal of Clinical Virology, 2020
- The novel Chinese coronavirus (2019‐nCoV) infections: Challenges for fighting the stormEuropean Journal of Clinical Investigation, 2020
- Outbreak of a novel coronavirusNature Reviews Microbiology, 2020
- Urea-mediated dissociation alleviate the false-positive Treponema pallidum-specific antibodies detected by ELISAPLOS ONE, 2019
- Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor AntagonistsClinical Gastroenterology and Hepatology, 2018
- Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving TofacitinibInflammatory Bowel Diseases, 2018
- Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel diseaseJournal of Crohn's and Colitis, 2014
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987